Navigation Links
Addition of trastuzumab may potentially equalize disease-free survival outcomes among obese and normal-weight patients
Date:12/8/2011

SAN ANTONIO A large, multicenter, randomized study has shown that obese patients with HER2-positive breast cancer have larger tumors, increased lymph node involvement and, when not treated with trastuzumab, poorer long-term outcomes than normal-weight patients.

This is the first time the relationship between obesity and HER2-positive breast cancer has been studied, according to Jennifer A. Crozier, M.D., a medical resident at Mayo Clinic, Jacksonville, who presented the results at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

"We knew that obesity was a risk factor for breast cancer," said Crozier. "However, we had not explored the relationship between body mass and how patients respond to treatment and disease-free survival (DFS)."

The study, known as N9831, included 3,017 patients who were initially classified into two categories based on World Health Organization body mass index (BMI) guidelines: normal-weight patients (BMI less than 30) and obese patients (BMI greater than 30). BMI was measured when patients began chemotherapy.

Researchers randomly assigned patients to treatment with only chemotherapy, with chemotherapy and sequential trastuzumab or with chemotherapy and concurrent trastuzumab.

When data were first examined, there were no significant differences in DFS between obese and normal-weight patients in any arm at three, five and seven years of follow-up. The team then subdivided normal-weight patients to determine if those patients considered overweight, with BMI between 25 and 29, might be affecting the analysis.

They found that obese patients and overweight patients had lower DFS rates of 70.6 percent and 65.9 percent, respectively, after seven years when not treated with trastuzumab compared with a rate of 74.7 percent among normal-weight patients also treated with chemotherapy alone. Results suggested that adding trastuzumab to treatment, particularly when received concurrently with chemotherapy, may potentially equalize DFS rates, with five-year rates of about 85 percent for normal-weight and overweight patients and 82.6 percent for obese patients.

Researchers observed these DFS rates among patients who received concurrent trastuzumab, regardless of BMI. Among patients treated with sequential trastuzumab, normal-weight patients appeared to have benefited more from the treatment than obese patients. Patients treated with chemotherapy alone had the worst observed DFS rate of the three groups, highlighting the potential importance of trastuzumab in treating HER2-positive breast cancer.

The researchers also alleviated the concern that hormonal differences in obese patients might undercut trastuzumab's effectiveness.

"Overall, we can see in the trends that weight management is going to be important in treating HER2-positive breast cancer," said Crozier. "The next step is to examine how weight management during different stages of treatment affects outcomes."


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. BIO-key(R) Announces Additional $245,000 in Third Quarter Public Safety Orders
2. BIO-key(R) Granted Additional Patent for Biometric Security Solution
3. Nine Additional Virginia Law Enforcement Agencies Deploy BIO-key(R) and DaPro Systems Solution
4. Nine Additional Virginia Law Enforcement Agencies Deploy BIO-key(R) and DaPro Systems Solution
5. Fujitsu Expands Support for Ethernet Networks With New Additions to XG Switch Product Line
6. Small addition to cancer drug may make big difference
7. Extinction of woolly mammoths may have been due to addition of a predator: Humans
8. BIO-key® Awarded Additional Large-Scale Fingerprint Biometric Contract
9. Connection between light at night (LAN) and cancer revealed in additional study
10. Connection between light at night and cancer revealed in additional study
11. Study finds massive flux of gas, in addition to liquid oil, at BP well blowout in Gulf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... , March 2, 2017 Australian stem cell ... (ASX: CYP), has signed an agreement with the Monash ... Monash Biomedicine Discovery Institute and Department of Pharmacology at ... a further preclinical study to support the use of ... asthma.  Asthma is a chronic, long ...
(Date:2/28/2017)... LOS ANGELES , Feb. 28, 2017   ... identity verification software globally, announces significant enhancements to new ... in May 2016. New products include mobile and desktop ... and DocX TM - a real time manual ... Acuant,s core idScan® technology provides the fastest and most ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... 2017  GlobeImmune, Inc. today announced it has entered ... 12,835,490 shares of its common stock to NantCell, Inc., ... with the sale of its common stock, NantCell has ... to GlobeImmune 200,000 shares, an estimated $2.0 million in ... are pleased to enter into this strategic agreement with ...
(Date:3/23/2017)... , March 23, 2017 NetworkNewsWire ... ... death, putting significant strain on health care systems, in terms ... diagnoses rises, so too does the development of innovative and ... side effects. Among the many types of cancer treatments, a ...
(Date:3/23/2017)... La. (PRWEB) , ... March 23, 2017 , ... ... industrial monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as ... customer applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has ...
(Date:3/22/2017)... MONICA, Calif. , March 22, 2017 /PRNewswire/ ... are proud to announce their extended partnership and ... will be headlined by the 21 st ... BIOMEDevice Boston, taking place May 3-4, 2017. ... Advanced Medical Technology Association (ADVAMED) President and CEO, ...
Breaking Biology Technology: